Butyrate (Sodium/Calcium Butyrate) 用于 Crohn's Disease
COral butyrate (4 g/day for 8 weeks) improved CDAI scores in open-label study. Controlled evidence still limited.
<\/script>\n`;
},
get iframeSnippet() {
const domain = 'gutcited.com';
const params = 'ingredient\u003Dbutyrate\u0026condition\u003Dibd\u002Dcrohns\u002Ddisease';
return ``;
},
get activeSnippet() {
return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet;
},
copySnippet() {
navigator.clipboard.writeText(this.activeSnippet).then(() => {
this.copied = true;
setTimeout(() => { this.copied = false; }, 2000);
});
}
}"
@keydown.escape.window="open = false"
@click.outside="open = false">
C
结论
Oral butyrate (4 g/day for 8 weeks) improved CDAI scores in open-label study. Controlled evidence still limited.
Key Study Findings
Randomized Controlled Trial
n=140
Double-blind
Impact of oral butyrate on clinical and biochemical parameters in IBD: A randomized placebo-controlled study …
Dose: None
vs: placebo plus conventional therapy
Outcome: clinical disease activity and fecal calprotectin
效果: None
p=0.013
研究人群: IBD patients (60 Crohn's disease, 80 ulcerative colitis)
In Vitro
Sodium butyrate alleviates DSS-induced inflammatory bowel disease by inhibiting ferroptosis and modulating ERK/STAT3 signaling and …
Dose: Low-dose and high-dose NaB
vs: DSS-induced IBD mice; 5-ASA control
Outcome: IBD symptom alleviation and ferroptosis inhibition
效果: None
None
研究人群: DSS-induced IBD murine model
In Vitro
Effects of Lactobacillus paracei JY062 Postbiotic on Intestinal Barrier, Immunity, and Gut Microbiota.
Dose: 5 mg/mL
vs: LPS-treated cell models
Outcome: Intestinal barrier function and gut microbiota
效果: None
None
研究人群: Caco-2 cells, RAW264.7 macrophages, fecal fermentation
Other
Association of Inflammatory Factors and Calcium Metabolism With Arthritis in Patients With Inflammatory Bowel Disease: …
Dose: None
vs: None
Outcome: Causal associations IBD → arthritis subtypes (MR)
效果: OR=1.21 (IBD→AS); OR=1.18 (IBD→PsA)
<0.001 (AS); 0.007 (PsA)
研究人群: Mendelian randomization study of IBD and arthritis
Observational Study
n=212
Microbiome multi-omics analysis reveals novel biomarkers and mechanisms linked with CD etiopathology.
Dose: None
vs: Healthy controls
Outcome: CD-specific microbiome signatures (AUC 0.94)
效果: AUC 0.94 in external validation
None
研究人群: Crohn's disease and ulcerative colitis patients
In Vitro
Effects of senotherapeutics on gut microbiome dysbiosis and intestinal inflammation in Crohn's disease: A pilot …
Dose: None
vs: Untreated Crohn's disease microbiota
Outcome: Gut microbiome modulation and inflammation
效果: None
None
研究人群: Crohn's disease fecal microbiota in SHIME model
Key Statistics
2
研究数量
200
受试者
↑
Positive
C
等级
Referenced Papers
Digestive and liver …
2026
5 次引用
Annals of medicine
2025
12 次引用
Nutrients
2025
7 次引用
Biomarker research
2025
6 次引用
Translational research : …
2025
4 次引用
Langenbeck's archives of …
2025
3 次引用
Mediators of inflammation
2025
2 次引用
BioFactors (Oxford, England)
2025
Frontiers in bioscience …
2025
ACS nano
2024
89 次引用
Gut microbes
2024
32 次引用
Gut microbiota and metabolites as predictors of biologics response in inflammatory bowel disease: A comprehensive systematic review.
Systematic Review
Microbiological research
2024
31 次引用
International immunopharmacology
2024
17 次引用
The American journal …
2024
11 次引用
Cellular and molecular …
2024
10 次引用
Poultry science
2024
9 次引用
Inflammatory bowel diseases
2024
5 次引用
Nutrients
2024
3 次引用
Journal of animal …
2024
Nutrients
2023
162 次引用
Digestion
2023
71 次引用
Gut microbes
2023
29 次引用
Microbiome
2023
28 次引用
Lipids in health …
2023
7 次引用
Gut microbes
2022
107 次引用
Gut microbes
2022
60 次引用
Nutrients
2022
54 次引用
Journal of Crohn's …
2022
23 次引用
Inflammatory bowel diseases
2022
21 次引用
PloS one
2022
9 次引用
International journal of …
2021
17 次引用
Neurogastroenterology and motility
2020
176 次引用
Journal of Crohn's …
2020
50 次引用
Gut microbes
2020
32 次引用
Frontiers in immunology
2019
3034 次引用
Gastroenterology
2019
276 次引用
Scientific reports
2019
124 次引用
Terapevticheskii arkhiv
2019
50 次引用
World journal of …
2019
45 次引用
Current opinion in …
2019
5 次引用
Current pharmaceutical design
2018
108 次引用
Journal of Crohn's …
2018
91 次引用
PLoS computational biology
2018
29 次引用
Journal of animal …
2018
15 次引用
Cell host & …
2017
399 次引用
Scientific reports
2017
391 次引用
Gastroenterology
2017
335 次引用
Best practice & …
2017
14 次引用
Innate immunity
2017
13 次引用
Digestion
2016
522 次引用
Journal of gastroenterology
2016
49 次引用
Recent advances in characterizing the gastrointestinal microbiome in Crohn's disease: a systematic review.
Systematic Review
Inflammatory bowel diseases
2015
222 次引用
Proceedings of the …
2014
1853 次引用
Gut
2014
1657 次引用
Gut
2013
311 次引用
Polish journal of …
2013
PloS one
2012
108 次引用
Dysbiosis of the faecal microbiota in patients with Crohn's disease and their unaffected relatives.
Other
Gut
2011
1055 次引用
Alimentary pharmacology & …
2005
227 次引用
Alimentary pharmacology & …
2003
179 次引用
Current opinion in …
2001
45 次引用
Current opinion in …
2001
38 次引用
Gut
2000
370 次引用
Current opinion in …
2000
21 次引用
Diseases of the …
1998
26 次引用
The Journal of …
1994
29 次引用
Digestive diseases (Basel, …
1993
29 次引用
Dosage & Usage
mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units
常用剂量
- general:
- 150-600 mg/day sodium or calcium butyrate
- ibdsupport:
- 300-600 mg three times daily (900-1,800 mg/day)
- butyrateenema:
- 100 mM butyrate enema for distal UC (clinical setting only)
上限： No established upper limit for oral supplements; most studies use 600-4,000 mg/day
研究中使用的剂量
| 剂量 | 持续时间 | 效果 | N |
|---|---|---|---|
| None | -- | Positive | 140 |
| Low-dose and high-dose NaB | -- | Positive | -- |
| 5 mg/mL | -- | Positive | -- |
| None | -- | Positive | -- |
| None | -- | Positive | 212 |
| None | -- | Positive | -- |
| None | -- | Negative | -- |
| None | -- | Mixed | -- |
最佳服用时间： With meals; enteric-coated formulations recommended to reach the colon
Safety & Side Effects
已报告的副作用
- ⚠ Unpleasant taste/odor (butyric acid has a strong rancid butter smell)
- ⚠ Mild GI discomfort (nausea, bloating)
- ⚠ Belching with butyric acid odor
- ⚠ Enteric-coated formulations reduce taste issues
已知相互作用
- ● 5-ASA medications (mesalamine) — additive anti-inflammatory effect (potentially beneficial in IBD)
- ● No significant adverse drug interactions known
可耐受最高摄入量： No established upper limit for oral supplements; most studies use 600-4,000 mg/day
在开始服用任何补充剂之前，请务必咨询您的医疗保健提供者。
Frequently Asked Questions
Does Butyrate (Sodium/Calcium Butyrate) help with Crohn's Disease?
Based on 2 studies with 200 participants, there is limited but promising evidence that Butyrate (Sodium/Calcium Butyrate) may support Crohn's Disease management. Our evidence grade is C (Some Evidence).
How much Butyrate (Sodium/Calcium Butyrate) should I take for Crohn's Disease?
Studies have used various dosages. A commonly studied range is 150-600 mg/day sodium or calcium butyrate. Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of Butyrate (Sodium/Calcium Butyrate)?
Reported side effects may include Unpleasant taste/odor (butyric acid has a strong rancid butter smell), Mild GI discomfort (nausea, bloating), Belching with butyric acid odor, Enteric-coated formulations reduce taste issues. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for Butyrate (Sodium/Calcium Butyrate) and Crohn's Disease?
We rate the evidence as Grade C (Some Evidence). This rating is based on 2 peer-reviewed studies with 200 total participants. The overall direction of effect is positive.
Related Evidence
其他成分用于 Crohn's Disease
Butyrate (Sodium/Calcium Butyrate) 用于其他健康状况
FDA 免责声明: 这些声明未经美国食品药品监督管理局（FDA）评估。本网站上的产品和信息无意用于诊断、治疗、治愈或预防任何疾病。所展示的证据等级基于我们对已发表的同行评审研究的分析，不构成医疗建议。在开始任何补充剂方案之前，请务必咨询您的医疗保健提供者。